

Second Quarter 2022 Earnings Presentation Nasdaq: STRM



Disclosure Statement

Actual results might differ materially from these statements due to a number of risks and uncertainties. Risks that may contribute to the uncertain nature of these statements are described in Streamline Health's periodic filings made with Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." Streamline Health undertakes no obligation to update any forward-looking statements or relevant risks, except as may be required by law.

Streamline Health (Nasdag: STRM)

© 2022 Streamline Health, Inc. All Rights Reserved.

SAFE HARBOR STATEMENT: FORWARD-LOOKING DISCLOSURE

This presentation contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, based on current management expectations. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and that can cause Streamline Health's actual results to differ. We caution you therefore to not place undue reliance on such statements.


TRADEMARKS

Product or company names referenced herein may be trademarks or registered trademarks of their respective owners



Streamline Health

Second Quarter 2022 & Recent Highlights



Streamline Health (Nasdaq: STRM)



eValuator Solutions Update



Closed largest ever eValuator deal and successfully entered market with professional fee module



Client success program continues to succeed and is a key differentiator





slowed implementations

Streamline Health (Nasdaq: STRM)

- Though hospitals have begun return to normal, IT department backlogs have



Avelead Solutions Update



Continuing to invest in innovation and service to create a strong foundation for long term growth



Maturing Cerner relationship and anticipate growth via this channel despite innovation focus



Successfully closed first booking with large Southwestern hospital system following a 9-month pilot program, significant growth potential within this client

Streamline Health (Nasdaq: STRM)



Financial Results


Income Statement

	Three Months Ended July 31, 2022	Three Months Ended July 31, 2021	Six Months Ended July 31, 2022	Six Months En July 31, 2
Revenue	\$6.0M	\$2.9M	\$11.9M	\$5
Operating Expenses	\$8.6M	\$5.3M	\$17.8M	\$10
Loss from Continuing Operations	(\$3.3M)	(\$0.1M)	(\$6.0M)	(\$2.
Net Loss	(\$3.3M)	(\$0.1M)	(\$6.1M)	(\$2.
Adj. EBITDA*	(\$1.1M)	(\$0.8M)	(\$2.4M)	(\$1.

*Streamline Health defines "adjusted EBITDA" as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees. Please see our press release for a reconciliation of non-GAAP Adjusted EBITDA to GAAP Net Income.

Streamline Health (Nasdaq: STRM)





Financial Results

Balance Sheet

Cash & Cash Equivalents

Total Current Assets

Total Current Liabilities

Total Bank Debt Outstanding

Streamline Health (Nasdaq: STRM)

As of January 31,	As of July 31, 2022
\$9	\$5.9M
\$1	\$11.2M
\$13	\$14.7M
\$1	\$10.0M





Looking Forward

Project continued growth of recurring SaaS revenue as a percentage of total revenue



Go-forward SaaS bookings expectation of \$3M - \$5M per quarter



Anticipate reaching cash generation during 3Q 2023

Streamline Health (Nasdaq: STRM)









Second Quarter 2022 Earnings Presentation Nasdaq: STRM

